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Abstract
Background: Protein C (PC) is one of the most important physiological inhibitors of coagulation proteases. Hereditary PC
deficiency causes a predisposition to venous thrombosis (VT). The genetic characteristics of PC deficiency in the Chinese
population remain unknown.
Methods: Thirty-four unrelated probands diagnosed with hereditary PC deficiency were investigated. PC activity and
antigen levels were measured. Mutation analysis was performed by sequencing the PROC gene. In silico analyses, including
PolyPhen-2, SIFT, multiple sequence alignment, splicing prediction, and protein molecular modeling were performed to
predict the consequences of each variant identified. One recurrent mutation and its relative risk for thrombosis in relatives
were analyzed in 11 families. The recurrent mutation was subsequently detected in a case (VT patients)-control study, and
the adjusted odds ratio (OR) for VT risk was calculated by logistic regression analysis.
Results: A total of 18 different mutations, including 12 novel variants, were identified. One common mutation, PROC
c.565C.T (rs146922325:C.T), was found in 17 of the 34 probands. The family study showed that first-degree relatives
bearing this variant had an 8.8-fold (95%CI=1.1–71.6) increased risk of venous thrombosis. The case-control (1003 vs. 1031)
study identified this mutation in 5.88% patients and in 0.87% controls, respectively. The mutant allele conferred a high
predisposition to venous thrombosis (adjusted OR=7.34, 95%CI=3.61–14.94). The plasma PC activity and antigen levels in
heterozygotes were 51.7366.92 U/dl and 75.1764.84 U/dl, respectively.
Conclusions: This is the first study on the genetic background of PC deficiency in the Chinese population. The PROC
c.565C.T mutation is the most frequent cause of PC deficiency as well as a prevalent risk factor for VT in Chinese
individuals. The inclusion of this variant in routine thrombophilic detection may improve the diagnosis and prevention of
venous thrombosis.
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Introduction
Protein C, the key component of the PC anticoagulant system, is
an important vitamin K-dependent protein that regulates the
physiological coagulation cascade by inactivating factors Va and
VIIIa upon activation by thrombin [1–3]. The mature PC
molecule is a single- chain, 62-kDa glycoprotein that is synthesized
by hepatocytes as a 461-amino acid precursor from which a 42-
amino acid signal peptide is cleaved. Protein C is composed of a c-
carboxy-glutamic acid residue (Gla) domain, two epidermal
growth factor (EGF)-like domains, a short activation peptide,
and a serine protease domain [4,5]. Thrombin cleaves PC at
Arg169, removes the activation peptide and generates activated
protein C (APC) [6]. In addition to its anticoagulant properties,
APC has anti-inflammatory and cytoprotective functions, which
are exerted when APC activating protease activated receptor-1
(PAR-1) [7,8]. The human protein C gene (PROC) is located on
chromosome 2q13-q14 and comprises nine exons spanning 11 kb
[9,10].
The most common genetic risk factors for venous thrombosis in
Whites, factor V Leiden (FV R506Q) and prothrombin G20210A
polymorphism, are rare in Eastern populations [11–13]. There-
fore, the three main physiological anticoagulant (antithrombin,
protein C, and protein S) deficiencies are important risk factors in
Asians, and their diagnosis is of great clinical interest [14,15].
Hereditary protein C deficiency (OMIM#176860) is usually
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increased risk of venous thrombosis and hereditary thrombophilia.
Heterozygous individuals have an approximately 7-fold increased
risk of venous thrombosis compared with normal individuals [16].
The homozygous (or compound heterozygous) state of protein C
deficiency is much more rare [17]. The overlap in the plasma
protein C levels between healthy individuals and PC heterozygotes
makes the discrimination between these two groups solely based
on a single plasma measurement challenging [18]. Genetic
determination is likely to be more powerful.
To date, a number of mutations in the PROC gene associated
with PC deficiency have been identified, but only a few of these
variants were observed in the Chinese population, and the genetic
characteristics of PC deficiency in Chinese patients have not been
studied. Here, we report the results of the genetic investigation of
protein C deficiency in 34 Chinese families and present a
prevalent causative variant for PC deficiency and venous
thrombosis.
Methods
Ethics Statement
This study was approved by the ethics committee of Union
Hospital, Huazhong University of Science and Technology and
complied with the principles expressed in the Declaration of
Helsinki. Written informed consent was obtained from all
participants.
Protein C-deficient patients and sample collection
A total of 34 unrelated probands diagnosed with hereditary
protein C deficiency and registered at the Hubei Clinical and
Research Center of Thrombosis and Hemostasis from 2008 to
2010 were investigated. The diagnosis was based on repeated low
plasma protein C activity measurements and a personal or family
history of symptomatic thromboembolic diseases.
Blood samples were collected from all subjects during a non-
acute phase of VT (at least one month after a VT incident), and
the patients had not received anticoagulant therapy for at least two
weeks before the collection. The blood sample was collected by
venipuncture into a vacutainer tube containing 1/10 volume of
0.105 mol/L trisodium citrate and was immediately centrifuged at
20006 g for 15 min. The platelet-poor plasma was stored at
280uC until assayed. High molecular weight genomic DNA was
isolated from white blood cells and standardized to 50 ng/ml.
Coagulation assays
Protein C, protein S, and antithrombin activities were assayed
on a Sysmex CA 7000 Analyzer (Sysmex, Japan) using commercial
reagents obtained from Dade Behring-Siemens Healthcare
Diagnostics, Germany. Protein C and antithrombin activities
were measured using a chromogenic substrate method. The APC-
cofactor activity of protein S was evaluated using a clotting
method. Protein C antigen was further tested by an enzyme-linked
immunosorbent assay using ZYMUTEST Protein C (Hyphen
BioMed, France). The normal ranges of these tests in our lab were
established in 78 healthy subjects.
The PROC gene analysis
The PROC gene was analyzed in each proband by PCR and
resequencing. All nine exons, including at least 100 bp flanking
intron regions, and the 59- and 39-untranslated regions of the
human protein C gene were amplified. Detailed amplification
conditions and the sequences of the oligonucleotide primers used
are available upon request. The amplified fragments were
sequenced on an ABI PRISM 3730XL automated sequencer
(Applied Biosystems). Identified variants were confirmed on a
second PCR product, sequencing on both strands. The variants
were designated according to current nomenclature and the
recommendations of the Human Genome Variation Society
(HGVS, http://www.hgvs.org/mutnomen/) and were checked
using the Mutalyzer program [19–21]. All new data have been
deposited in GenBank under accession numbers NM_000312.3
and NP_000303.1. Each novel variant was then detected in 50
normal individuals (100 alleles) using direct sequencing.
In silico analysis of novel amino acid changes
The possible impact of novel coding sequence changes (amino
acid substitutions) on the structure and function of PC was assessed
using two bioinformatics tools, Sorting Intolerant From Tolerant
(SIFT, http://sift.jcvi.org) and Polymorphism Phenotyping-2
(PolyPhen-2, http://genetics.bwh.harvard.edu/pph2/) [22,23].
The UniProtKB Protein ID ‘‘P04070’’ and Protein Ensembl
ENSP ID ‘‘ENSP00000234071’’ were used, respectively.
The conservation of the affected amino acids were further
checked by multiple sequence alignment (HomoloGene, http://
www.ncbi.nlm.nih.gov/sites/entrez) with sequences from Pantro-
glodytes, Canis lupus familiaris, Bos taurus, Mus musculus, Rattus
norvegicus, and Gallus gallus.
Splicing efficiency prediction
The effect of exon-intron boundary variants on the efficiency of
splice processing was predicted by two web server programs:
SplicePort (http://spliceport.cs.umd.edu/) and Alternative Splice
Site Predictor (ASSP, http://www.es.embnet.org/,mwang/assp.
html) [24,25].
Protein molecular modeling
The molecular structures of the wild-type and mutant proteins
were modeled using Swiss model workspace (http://swissmodel.
expasy.org/) [26] and noc-3.01 software based on the tridimen-
sional crystal structure of PC (PDB ID: 3F6U) [27].
Recurrent mutation detection in venous thrombosis
patients and controls
The PROC c.565C.T mutation, which was common among
the probands, was subsequently detected in an independent case-
control study to evaluate the OR of this variant for venous
thrombosis in the Chinese population.
This secondary study included consecutive unrelated patients
(n=1003) who were diagnosed with venous thrombosis at the
Hubei Clinical and Research Center of Thrombosis and
Hemostasis from 2008 to 2011. The thrombosis incidents were
validated based on clinical manifestations, D-dimer levels, Doppler
ultrasound (for deep vein thrombosis), ventilation perfusion lung
scan, and/or computed tomography angiography (for pulmonary
embolism). Age- and sex-matched controls (n=1031) without an
individual or family history of VT were enrolled from a
community screening program in the same regions during the
same time window. Demographic data and acquired thrombotic
risk factors were recorded. Blood samples were collected from all
participants.
All of the participants included in the case-control study were
central Chinese. To test whether this PC variant was also common
in populations from other regions of China, we recruited a cohort
of 492 healthy individuals (43.9% female) who were evaluated for
routine physical check-up in Shanghai (Dongfang Hospital,
eastern China) in February 2012. The healthy Shanghai
Genetic Background of PC Deficiency in Chinese
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history of thrombosis. Blood samples were collected, and genomic
DNA was extracted and prepared for genotyping.
The c.565C.T mutation was genotyped using the PCR-RFLP
method. The mutagenic primers 59-TCCTTGAACCCTG-
CACTGTGGCAA-39 and 59-TTTCAGGTGACTACGC-
TTCTTCTCCATGC-39 were employed. The underlined and
italicized base G in the lower primer was used to introduce a Hin6
I restriction site into the normal allele. In contrast, the underlined
and italicized base A was used to eliminate an adjacent restriction
site. Therefore, only the PCR product of the common allele has a
Hin6 I recognition site. Altogether, 10 ml of PCR product was
digested with 5 U of Hin6 I (Fermentas, Canada) for 3 hours at
37uC and then subjected to 2% agarose gel electrophoresis. To
verify the genotyping results determined by PCR/RFLP assay, up
to 192 DNA samples were randomly selected and subjected to
sequencing.
Family analysis of the recurrent mutation
To avoid bias, probands were excluded, and analyses were
performed on first-degree relatives only. Included families were
composed of at least two family members (one c.565C.T carrier
and one non-carrier). Six families were excluded because they did
not meet the criteria. In total, 49 family members from 11 families
were enrolled to estimate the thrombotic risk associated with the
recurrent mutation. The annual incidence of thrombosis was
calculated by dividing the number of events in each group (carriers
and non-carriers) by the total number of patient-years of follow-
up. For each individual, years of follow-up were defined as the
time from the date of birth to either the date of the first episode of
venous thrombosis, if any, or December 2011. The relative risks
were calculated using only the first thrombotic event during
follow-up.
Statistical analysis
For continuous variables, differences between groups were
analyzed by a Student’s t-test or Mann-Whitney U-test, depending
on the normality of the data. A chi-squared test was used for
categorical variables. Deviations from Hardy-Weinberg expecta-
tions were assessed using both Fisher’s Exact test and chi-squared
test. Multivariate logistic regression analysis was used to calculate
the OR of the c.565C.T mutation for venous thrombosis
adjusted for selected confounders (age, gender, smoking status,
alcohol abuse, malignant tumor, type 2 diabetes, sedentariness/
immobilization, and pregnancy/puerperium). A Cox regression
analysis was performed to estimate the relative risk (hazard ratio)
for thrombosis in first-degree relatives with the c.565C.T
mutation, adjusted for age and gender. Statistical power was
estimated using the Power and Sample (PS) size calculation
program [28]. A two-tailed P,0.05 was considered statistically
significant. Analyses were performed using SPSS version 12.0
software (SPSS Inc., Chicago, IL).
Results
Mutation profiles
Eighteen different genetic variants (12 novel) were identified in
32 of the 34 probands (94.1%). No candidate mutations were
found in the other two subjects, most likely due to gross insertion/
deletion of the PROC gene. The mutation profiles consisted of 14
missense mutations, two splice site mutations, one small deletion,
one small duplication, and one 39-untranslated region variant.
Each novel variant identified in a proband was shown to
Table 1. Mutation profiles, laboratory, and clinical data of for patients with PC deficiency.
Patient No. Age Clinical data PC:A (U/dl) PC:Ag (U/dl) NT exchange AA substitution Ref.
PC1 15 DVT 6.3 12.6 c.889G.C c.1258G.T p.Asp297His p.Val420Leu novel novel
PC3 64 DVT 40.4 48.3 c.*73C.T - novel
PC4 33 DVT 52.9 58.8 c.524G.A p.Cys175Tyr novel
PC6 32 DVT/MVT 36.4 49.2 c.716dupG p.Ala240GlyfsX17 novel
PC7 55 DVT 52.1 31.5 c.632G.A p.Arg211Gln [32]
PC11 24 DVT/PE 9.9 9.2 c.349_352del c.541T.G p.Phe118AlafsX16 p.Phe181Val Novel [33]
PC12 45 DVT 61.7 53.4 c.400+5G.A - [29]
PC15 65 DVT 49.3 61.7 not found - -
PC16 46 DVT 44.1 53.3 c.316T.G p.Cys106Gly novel
PC17 46 DVT/PE 57.7 65.2 c.889G.C c.891C.T p.Asp297His novel novel
PC19 44 DVT 30.4 76.7 c.935C.T p.Ser312Leu [34]
PC20 37 DVT 40.9 38.3 c.658C.T p.Arg220Trp [29]
PC22 49 DVT 48.5 53.3 not found - -
PC25 42 DVT/AIS 39.4 26.7 c.541T.G c.980A.T p.Phe181Val p.Glu327Val [33] novel
PC27 46 DVT 48.7 42.4 c.208A.G p.Lys70Glu novel
PC28 54 DVT 40.0 53.0 c.237+5G.A - novel
PC29 48 DVT 60.0 88.1 c.669C.A p.Ser223Arg novel
PC31 64 DVT 44.2 42.4 c.541T.G p.Phe181Val [31]
others 38–67 DVT 40.4–62.3 68.7–83.0 c.565C.T p.Arg189Trp [34]
Mutations were designated according to the HGVS nomenclature for variants, comparing with the NCBI Reference Sequences NM_000312.3 and NP_000303.1. Patients
with two nucleotide substitutions indicated compound heterozygotes. NT=nucleotide. AA=amino acid. Ref.=References. DVT=deep vein thrombosis.
MVT=mesenteric vein thrombosis. PE=pulmonary embolism. AIS=acute ischemic stroke.
doi:10.1371/journal.pone.0035773.t001
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novel variants were absent in all 50 healthy individuals, suggesting
that they are not common polymorphisms. The mutation profiles
are summarized in Table 1.
Missense mutations
A total of 14 missense mutations resulted in amino acid
substitutions. Eight are reported for the first time here. A multiple
sequence alignment among selected species showed that seven of
the newly identified mutations led to substitutions of highly
conserved amino acids (Figure 1). Although Lys70 (basic amino
acid) is not conserved, Glu (acidic amino acid) is never present at
this site in the evaluated species. Novel missense mutations of
p.Cys175Tyr, p.Asp297His, and p.Val420Leu were predicted to
be deleterious by both the SIFT and PolyPhen-2 algorithms. The
other four mutations (p.Lys70Glu, p.Cys106Gly, p.Ser223Arg,
and p.Glu327Val) were predicted to be damaging by one
algorithm. The location of each affected amino acid and the
correlative structure of mutant PC are depicted in Figure 2.
Null mutations
Five of the detected variants were suspected to result either in
the complete absence of the gene product or in the expression of a
non-functional protein; these mutations were defined as null
mutations, and four of them are novel. The frameshift mutations
c.719dupG and c.349_352del might produce a premature
termination codon and lead to the production of a truncated
protein. The c.237+5G.A mutation occurs in the donor splice site
of intron C. This substitution changed the splice site scores to
0.000 from original scores of 7.137 and 0.180 assigned by the
splicing efficiency prediction programs ASSP and SplicePort,
respectively. The closest candidate splice site was 46 bp down-
stream from the normal splice site. No matter whether the cryptic
splice site would be used, this should result in an abnormal
translation product. The c.*73C.T variant, 73 bp downstream
from the stop codon, completely cosegregated in the PC3 family
and was absent in 50 control subjects. This mutation might affect
the stability of the PC mRNA.
Recurrent mutation detection in patients and controls
Seventeen of the 34 probands (50%) carried the same mutation,
c.565C.T (p.Arg189Trp), in exon 7. The recurrent mutation was
then evaluated in an independent case-control study by PCR/
RFLP (Figure 3). The genotyping data from the RFLP assays were
completely consistent with those obtained by sequencing. The
demographic data and acquired thrombotic risk factors of all
Figure 1. Multiple sequence alignment highlighting the affected amino acids among selected species. The conservation degree of the
affected amino acids was evaluated in sequences from Homo sapiens (NP_000303.1), Bos taurus (NP_001159984.1), Canis lupus familiaris
(NP_001013871.1), Gallus gallus (NP_989772.1), Mus musculus (NP_032960.3), Pan troglodytes (XP_515775.3), and Rattus norvegicus (NP_036935.1).
doi:10.1371/journal.pone.0035773.g001
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mutation was identified in 59 (5.88%) venous thrombosis patients
and 9 (0.87%) controls. The homozygous genotype was absent in
all subjects. As illustrated in Table 3, the observed OR of this
mutation was 6.91 (95%CI=3.42–13.98; P=4.67610
210). Mul-
tivariate logistical regression analysis revealed that the association
between the variant and VT was still significant (OR=7.34;
95%CI=3.61–14.94; P=3.88610
28) after adjustment for age,
Figure 2. Structure models of the wild-type and mutant PC proteins. The amino acid number was designated according to the previous
nomenclature described in the Human Gene Mutation Database. That is, the first 42 amino acids (signal peptide) is subtracted. The wild-type amino
acids are shown in yellow and the mutants are shown in red. The D255H and the E285V mutations are also displayed in a solid surface model (G, H) in
which the electrostatic potential is clearly indicated.
doi:10.1371/journal.pone.0035773.g002
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diabetes, sedentariness/immobilization, and pregnancy/puerperi-
um in the dominant model. Meanwhile, this mutation was also
detected and confirmed in 4 of the 492 (0.81%) healthy
participants from Shanghai, indicating that this mutation is not
restricted to the central Chinese population and is likely to be
prevalent in the general population.
Thrombotic risk in first-degree relatives with the
c.565C.T mutation
As shown in Table 4, the incidence of thrombosis was greater in
first-degree relatives with the c.565C.T mutation (7.9 per 1000
person-years) compared with those without this mutation (0.8 per
1000 person-years), with a relative risk of 8.8 (95%CI=1.1–71.6)
for thrombosis.
Discussion
Protein C deficiency is known to be associated with an increased
risk of VT and its genetic background has been analyzed in several
populations [29–31]. In the present study, we systematically
investigated the genetic characteristics of PC deficiency in the
Chinese population.
A total of 18 different mutations, including one recurrent
mutation, were identified in 34 probands. Six of the detected
variants (c.400+5G.A, p.Phe181Val, p.Arg189Trp,
p.Arg211Gln, p.Arg220Trp, and p.Ser312Leu) have been report-
ed previously as disease-causing mutations [29,32–34].
Eight novel coding sequence variants contributed to seven
amino acid exchanges. The variant p.Lys70Glu is located in the
Gla domain, which is involved in the interaction between PC and
anionic phospholipid surfaces [35]. This alteration creates a new
Glu residue and changes the charge nature of this site, which
might reduce the efficiency of the interaction with phospholipid
membranes. The p.Cys106Gly and p.Cys175Tyr variants elimi-
nate Cys residues that are important for disulfide bond formation
in the EGF-1 and EGF-2 domains (Figure 2A–2B), respectively.
These mutations might result in the production of an aberrant
multimer or high molecular weight complex [36]. Variants in the
enzymatic serine protease domain (p.Ser223Arg, p.Asp297His,
p.Glu327Val, and p.Val420Leu) are located adjacent to either the
serine protease active site triad or the substrate binding region
Figure 3. PROC c.565C.T variant detection by PCR-RFLP and direct sequencing. (A) Electrophoretic patterns following Hin6 I digestion.
PCR products were 173 bp. Only amplicons with the wild-type sequences were digested, yielding two bands of 143 bp and 30 bp. The digestion
products were separated by 2% agarose gel electrophoresis. M, DNA marker with 50-bp ladder. Lanes 1, 2, and 4–6, normal individuals. Lane 3,
heterozygous individual for the variant. (B) Chromatograms obtained by sequencing. Left, wild-type; Right, heterozygote.
doi:10.1371/journal.pone.0035773.g003
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integrity and stability of the heavy chain and attenuate the
catalytic activity of the protein [37].
The three novel null mutations (c.237+5G.A, c.349_352del,
c.719dupG) are evidently detrimental because they either impair
mRNA splicing by disrupting the consensus sequences of the exon-
intron boundary or produce a premature stop codon. Abnormal
translation products may not be stable in vivo due to nonsense-
mediated mRNA decay [38,39]. The c.*73C.T mutation is
located in the untranslated region of the last exon. The 39-
untranslated region is essential for the posttranscriptional regula-
tion of mRNA expression. Mutations in this region almost always
reduce the stability and half-life of transcripts [40,41].
The recurrent c.565C.T variant (p.Arg189Trp, R147W, or
rs146922325:C.T) was identified in 17 probands, accounting for
half of the cases of PC deficiency. The retrospective family study
showed that first-degree relatives bearing this variant had an 8.8-
fold increased risk of venous thrombosis. The statistical power of
this analysis is approximately 0.989, with a type I error probability
of 0.01. However, the confidence intervals was wide due to the
small number of family members enrolled and the low incidence of
thrombosis in the non-carrier group. A larger prospective study
will be required to confirm our observations.
The R147W substitution is adjacent to the EGF-2 domain at
the C-terminal of the light chain and may impair the interaction of
PC with other molecular such as thrombin-thrombomodulin
complex, substrate, or phospholipid [42]. Further functional
studies are required to define the deleterious effect of this mutation
on the activation of PC, the inactivation of FVa by APC, and the
cytoprotective role of APC. This missense mutation was first
described in a family with PC deficiency as well as an
asymptomatic individual in 1995 [34,43]. Consistent with previous
studies, our analysis showed that the heterozygous state is
associated with decreased functional activity (40.4–62.3 U/dl)
Table 2. Data from participants enrolled in the secondary
case-control study.
Variable Cases Controls P
No. % No. %
Age (years) 51.45614.36 50.26614.52 0.063
Sex 0.970
Male 532 53.04% 546 52.96%
Female 471 46.96% 485 47.04%
Smoking 0.009
Yes 227 22.6% 185 17.9%
No 776 77.4% 846 82.1%
Alcohol drinker 0.717
Yes 117 11.7% 115 11.2%
No 886 88.3% 916 88.8%
Malignant tumor
1.207610
213
Yes 65 6.5% 5 0.5%
No 938 93.5% 1026 99.5%
T2DM 0.037
Yes 42 4.2% 26 2.5%
No 961 95.8% 1005 97.5%
Sedentariness 0.031
Yes 23 2.3% 11 1.1%
No 980 97.7% 1020 98.9%
Pregnancy/
puerperium
Yes 26 2.6% 14 1.4% 0.045
No 977 97.4% 1017 98.6%
Years of age were expressed as mean6standard deviation. Age of cases: age at
the first incident. Age of controls: age at enrollment. Age was further divided
into three levels: under 40 years, 40 to 60 years, and over 60 years.
Sedentariness/immobilization reflects the 4 weeks prior to the venous
thrombosis incident. A Chi-squared test was used to compare the differences
between groups according to gender, smoking status, alcohol abuse, malignant
tumor, type 2 diabetes, sedentariness/immobilization, and pregnancy/
puerperium. A Student’s t test was used to compare the mean ages of the cases
and controls. VT=venous thrombosis. T2DM=type 2 diabetes mellitus.
doi:10.1371/journal.pone.0035773.t002
Table 3. Association between the PROC c.565C.T and venous thrombosis in the Chinese population.
PROC c.565C.T Cases Controls Without adjustment After adjustment*
No. % No. % OR 95%CI P OR 95%CI P
C/C 944 94.12% 1022 99.13% 1 - - 1 - -
C/T 59 5.88% 9 0.87% 7.10 3.50–14.39 3.31610
210 7.34 3.61–14.94 3.88610
28
MAF - 2.94% - 0.44% 6.91 3.42–13.98 4.67610
210 -- -
Test for H-W equilibrium in controls: P=0.89. CI=confidence interval. MAF=minor allele frequency.
*Data were analyzed by logistic regression adjusted for age, gender, smoking status, alcohol abuse, malignant tumor, type 2 diabetes, sedentariness/immobilization,
and pregnancy/puerperium.
doi:10.1371/journal.pone.0035773.t003
Table 4. Family analysis of thrombotic risk in c.565C.T
carriers and non-carriers.
Carriers Non-carriers
Number 20 29
Male/Female 12/8 16/13
Age at first thrombosis, median (range) 51.5 (49–61) 51
Years of follow up 890 1264
Number of VT events 7 1
Events per 1000 person-years (95%CI) 7.9 (7.6–8.1) 0.8
Relative risk for thrombosis (95% CI)* 8.8 (1.1–71.6) 1
*Data were analyzed using a Cox regression model adjusted for age and
gender.
doi:10.1371/journal.pone.0035773.t004
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indicating type II PC deficiency. This variant is believed to be a
rare mutation and the corresponding minor allele frequency in
dbSNP is 0.000. Because its prevalence, a case-control study was
further conducted. This variant was also present in 9 out of the
1031 control subjects (0.87%) and was significantly associated with
VT risk. The statistical power of our analysis is approximately
0.999, with a type I error probability of 0.01. In combination with
the genotyping data from the 492 DNA samples from Shanghai,
the c.565C.T variant was present in approximately 0.85%
(95%CI=0.38%–1.31%) of the general population. The carrier
rate of this variant allele is relatively lower than that of factor V
Leiden (5%–10%) and prothrombin G20210A (2%–4%), two
polymorphisms that confer moderate predisposition to VT in
Whites [44]. However, it is more common than the antithrombin
Cambridge II variant (approximately 0.2%) [45] and other rare
but severe anticoagulant protein (AT, PC, and PS) mutations. One
previous study [46] showed that the estimated prevalence of
protein C deficiency in the general Chinese population is
approximately 0.29%. In their study, only subjects with PC
activity below the 1
st percentile were selected for DNA mutation
analysis and considered to have ‘‘PC deficiency’’. Subjects with a
PC level between the 1
st and 2.5
th percentiles might also have a
genetic defect. Therefore, these genetic variants might have been
missed. The PROC c.565C.T was one such of the missed
mutations. When this moderate mutation is taken into account,
however, it is clear that PC deficiency has been underestimated
and may be more frequent in the Chinese population than in
Japanese or European populations [47,48].
In conclusion, we investigated the genetic background of PC
deficiency in the Chinese population for the first time and
identified one recurrent variant as well as 17 other mutations. The
NM_000312.3:c.565C.T mutation is not only the most frequent
variant for PC deficiency but also a significant risk factor for
venous thrombosis in Chinese individuals. Although this variant
was identified about 16 years ago as a rare mutation in Western
populations, its high prevalence and potential clinical significance
in the Chinese population was not appreciated until now. The
prevalence of and the thrombotic risk associated with this
mutation in other populations (especially other Asian populations)
should be further evaluated. This genetic detection may be
included in the routine thrombophilia screening, and carriers of
this variant may benefit from early diagnosis and better prevention
[49].
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